Genea Biocells US, Inc. is a neuromuscular disease-focused preclinical stage company utilizing a proprietary technology platform for the accelerated development of drugs to treat neuromuscular diseases. These rare orphan diseases present an area of particularly high unmet medical need, for which no treatment options exist, and disease afflicted populations where patients are primarily children. Genea Biocells has developed a proprietary skeletal muscle differentiation method used to generate disease affected skeletal muscles for disease modeling and assay development. Genea Biocells’ screening approach makes use of a highly curated repurposed chemical library of compounds with favorable toxicity profiles, paving an accelerated path for regulatory approval of lead compound hits. Genea Biocells is based in San Diego, California and originated from the Australian Genea group, a public, unlisted company that has been operating world leading IVF clinics since 1985.
See also: http://www.geneabiocells.com